文献速递耳科与耳神经小儿耳鼻咽喉

2型糖尿病患者听力损失特征:系统综述与Meta分析

Characteristics of Hearing Loss in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.
PubMed 文献 · Otolaryngol Head Neck Surg · 2025-08-04

该系统综述与Meta分析纳入39项研究、88,395例2型糖尿病患者和20,337例对照,评估2型糖尿病与听力损失的关系。2型糖尿病患者临床显著听力损失的患病率和相对风险均显著高于对照(53.0% vs 25.2%;RR=2.3,95%CI:1.1-4.8)。作者认为应将听力评估和管理纳入2型糖尿病患者的常规照护。

要点

  • 2型糖尿病患者临床显著听力损失患病率为53.0%,显著高于对照组的25.2%(差值27.7%,p<.0001)。
  • 2型糖尿病患者听力损失相对风险为对照的2.3倍(RR=2.3,95%CI:1.1-4.8)。
  • 2型糖尿病组以感音神经性听力损失为主(46.2%),其次为混合性(10.4%)和传导性(5.0%)。

核心结论

  • 该Meta分析提供了2型糖尿病患者听力损失患病率和相对风险的最新估计,涵盖分类、侧别和程度。
  • 2型糖尿病患者听力损失风险显著增加,作者强调应将听力评估和管理纳入2型糖尿病患者的常规照护。

研究设计与样本

  • 按PRISMA指南对CINAHL、Cochrane Library、PubMed和SCOPUS数据库进行系统综述,纳入评估2型糖尿病与听力损失的研究。
  • 共纳入39项研究,包括88,395例2型糖尿病患者和20,337例对照。
  • 主要结局指标包括连续测量均值、比例(%)、比例差(∆)以及带95%置信区间的相对风险(RR)。

主要发现

  • 2型糖尿病组平均年龄50.3岁(范围19-96岁),对照组46.7岁(范围19-76岁);女性分别占63.8%和64.3%。
  • 2型糖尿病组平均糖尿病病程9.1年(95%CI:8.1-10.1),平均HbA1c为8.4%(95%CI:8.1-8.6),对照组为4.8%(95%CI:3.9-5.7)。
  • 2型糖尿病组临床显著听力损失患病率53.0% vs 对照组25.2%,差值27.7%(p<.0001),RR=2.3(95%CI:1.1-4.8)。
  • 2型糖尿病组中传导性听力损失占5.0%、感音神经性占46.2%、混合性占10.4%。
  • 按WHO标准,2型糖尿病组轻度(26-40 dB)22.1%、中度(41-60 dB)25.5%、重度(61-80 dB)8.5%、极重度(>80 dB)1.7%,与对照组比较差异均有统计学意义(p≤.0001)。

关键数值与推荐

  • 临床显著听力损失:2型糖尿病组53.0% vs 对照组25.2%(差值27.7%,p<.0001;RR=2.3,95%CI:1.1-4.8)。
  • 听力损失类型(2型糖尿病组):传导性5.0%、感音神经性46.2%、混合性10.4%。
  • WHO听力损失程度(2型糖尿病组):轻度(26-40 dB)22.1%、中度(41-60 dB)25.5%、重度(61-80 dB)8.5%、极重度(>80 dB)1.7%,与对照组比较p≤.0001。
  • 侧别(2型糖尿病组):单侧15.0%(与对照组比较p=.008)、双侧29.6%(与对照组比较p<.0001)。

临床怎么用

  • 作者认为,2型糖尿病患者听力损失风险显著增加,应将听力评估和管理纳入其常规照护。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

METHODS: A systematic review of CINAHL, Cochrane Library, PubMed, and SCOPUS databases was conducted according to PRISMA guidelines to identify studies evaluating T2DM and hearing loss. Primary outcome measures included continuous measures (mean), proportions (%), proportional difference (∆), and relative risks (RR) with 95% confidence intervals (CI). RESULTS: A total of 39 studies with 88,395 patients with T2DM and 20,337 controls were included. The mean ages of the T2DM and control groups were 50.3 (range: 19-96) and 46.7 (range: 19-76), respectively, with females comprising 63.8% and 64.3% of the groups. The mean duration of diabetes in the T2DM group was 9.1 years (95% CI: 8.1-10.1), and mean HbA1c of 8.4% (95% CI: 8.1-8.6), while the control group had 4.8% (95% CI: 3.9-5.7). Patients with T2DM had significantly higher prevalence and relative risk of clinically significant hearing loss compared to controls (53.0% vs 25.2%; ∆ = 27.7%, p < .0001; RR = 2.3, 95% CI: 1.1-4.8). In T2DM, 5.0% had conductive, 46.2% sensorineural, and 10.4% mixed hearing loss. According to WHO criteria, the T2DM group exhibited 22.1% mild (26-40 dB), 25.5% moderate (41-60 dB), 8.5% severe (61-80 dB), and 1.7% profound (>80 dB) hearing loss all with statistically significant differences compared controls (p ≤ .0001). In the T2DM group, data on laterality showed 15.0% unilateral and 29.6% bilateral hearing loss, both significantly higher than the controls (p = .008, p < .0001). CONCLUSION: This meta-analysis provides most updated estimates of the prevalence and relative risk of hearing loss in patients with T2DM, including details on the classification, laterality, and degrees. The significantly increased risk highlights the importance of incorporating hearing assessments and management into routine care for patients with T2DM.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Kim CH, Lauritsen KL, Nguyen SA, et al. Characteristics of Hearing Loss in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Otolaryngol Head Neck Surg. 2025. PMID: 40760922. doi:10.1002/ohn.1378

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。